It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is associated with metaplastic changes in the pancreas but the transcriptional program underlying these changes is incompletely understood. The zinc finger transcription factor, PRDM3, is lowly expressed in normal pancreatic acini and its expression increases during tumorigenesis. Although PRDM3 promotes proliferation and migration of PDAC cell lines, the role of PRDM3 during tumor initiation from pancreatic acinar cells in vivo is unclear. In this study, we showed that high levels of PRDM3 expression in human pancreas was associated with pancreatitis, and well-differentiated but not poorly differentiated carcinoma. We examined PRDM3 function in pancreatic acinar cells during tumor formation and pancreatitis by inactivating Prdm3 using a conditional allele (Ptf1aCreER;Prdm3flox/flox mice) in the context of oncogenic Kras expression and supraphysiological cerulein injections, respectively. In Prdm3-deficient mice, KrasG12D-driven preneoplastic lesions were more abundant and progressed to high-grade precancerous lesions more rapidly. This is consistent with our observations that low levels of PRDM3 in human PDAC was correlated significantly with poorer survival in patient. Moreover, loss of Prdm3 in acinar cells elevated exocrine injury, enhanced immune cell activation and infiltration, and greatly increased acinar-to-ductal cell reprogramming upon cerulein-induced pancreatitis. Whole transcriptome analyses of Prdm3 knockout acini revealed that pathways involved in inflammatory response and Hif-1 signaling were significantly upregulated in Prdm3-depleted acinar cells. Taken together, our results suggest that Prdm3 favors the maintenance of acinar cell homeostasis through modulation of their response to inflammation and oncogenic Kras activation, and thus plays a previously unexpected suppressive role during PDAC initiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Macau, Cancer Centre, Faculty of Health Sciences, Macau SAR, China; University of Macau, Institute of Translational Medicine, Faculty of Health of Sciences, Macau SAR, China
2 Sun Yat-sen University, Laboratory of General Surgery, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
3 University of Macau, Cancer Centre, Faculty of Health Sciences, Macau SAR, China (GRID:grid.12981.33); Duke-NUS Medical School, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
4 University of British Columbia, Department of Cellular and Physiological Sciences, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
5 University of Macau, Cancer Centre, Faculty of Health Sciences, Macau SAR, China (GRID:grid.17091.3e); University of Macau, Institute of Translational Medicine, Faculty of Health of Sciences, Macau SAR, China (GRID:grid.17091.3e)
6 University of Tokyo, Department of Hematology and Oncology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
7 University of Macau, Cancer Centre, Faculty of Health Sciences, Macau SAR, China (GRID:grid.26999.3d); University of Macau, Institute of Translational Medicine, Faculty of Health of Sciences, Macau SAR, China (GRID:grid.26999.3d)
8 University of California-San Diego, Department of Pediatrics and Cellular and Molecular Medicine, La Jolla, USA (GRID:grid.217200.6) (ISNI:0000 0004 0627 2787)
9 University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)